Table 1.
Number of women and children by treatment group in the ANRS 1201/1202 DITRAME PLUS study of prevention of mother-to-child transmission of HIV
| ZDV+3TC+NVPsd | ZDV+NVPsd | ZDV | |
|---|---|---|---|
| (2002–2003) | (2001–2002) | (1995–2000) | |
| Women enrolled | 373 | 420 | 351 |
| Excluded | 1 | 18 | 5 |
| (HIV-2 infection only) | (1) | (16) | (5) |
| Women analysed | 372 (100%) | 402 (100%) | 346 (100%) |
| Lost to follow-up before delivery | 23 (6.2%) | 22 (5.5%) | 11(3.2%) |
| Women who gave birth | 349 | 380 | 335 |
| Multiple birth outcomes excluded (stillbirth) | 17 † (0) | 21 # (1) | 4 † (0) |
| Single or first births analysed | 349 (100%) | 380 (100%) | 335 (100%) |
| Stillbirths | 13 (3.7%) | 5 (1.3%) | 4 (1.2%) |
| Livebirths analysed | 336 (100%) | 375 (100%) | 331 (100%) |
| Not tested for paediatric diagnosis (died before day 8) | 7 (2.1%) (4) | 14(3.7%) (6) | 11 (3.3%) (5) |
| Included in the transmission analysis | 329 (100%) | 361 (100%) | 320 (100%) |
| Tested HIV positive ≤week 6 | 15 (4.6%) | 23 (6.4%) | 41 (12.8%) |
| Confirmed in utero infection (day 1 or 2) | 7 | 10 | 3 |
| Probable in utero infection (day 3 or 4) | 3 | 4 | 2 |
| Intra partum or early postnatal infection | 3 | 8 | 17 |
| Timing of peripartum infection unknown | 2 | 1 | 19 |
†
second birth among twins;
#
second birth among 17 twin births, second and third
births among two triplets
3TC = lamivudine; NVPsd = single-dose nevirapine during labour; ZDV = zidovudine